Related Experiment Video
Updated: Apr 28, 2026
10:55
Assays for Studying the Role of Vitronectin in Bacterial Adhesion and Serum Resistance
Published on: October 16, 2018
7.1K
Expression and purification of bioactive, low-endotoxin recombinant human vitronectin
Michael M Halford1, Yi-Chao He2, Steven A Stacker2
1Tumour Angiogenesis Program, The Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria, Australia.
Biotechniques
|June 14, 2014
Summary
We developed a cost-effective method to produce high-purity recombinant human vitronectin (rhVTN). This process yields large quantities of bioactive rhVTN, suitable for various cell culture applications, including clinical settings.
Area of Science:
- Biochemistry
- Cell Biology
- Biotechnology
Background:
- Vitronectin (VTN) is a key glycoprotein in plasma and extracellular matrix.
- Bioactive recombinant human vitronectin (rhVTN) is crucial for cell culture and clinical applications.
- Existing methods for rhVTN production are often costly and yield high endotoxin levels.
Purpose of the Study:
- To develop an inexpensive, high-yield method for producing bioactive rhVTN.
- To efficiently remove endotoxins from rhVTN preparations.
- To facilitate the use of rhVTN in endotoxin-sensitive applications.
Main Methods:
- Modified a heparin-based affinity chromatography procedure.
- Utilized autoinduction expression in Escherichia coli for VTN production.
- Solubilized VTN inclusion bodies using urea and purified via chromatography.
Main Results:
- Achieved improved yield of recombinant human vitronectin.
- Successfully removed endotoxins to very low levels.
- Demonstrated the production of large quantities of bioactive rhVTN.
Conclusions:
- The described method provides a low-cost, high-yield source of endotoxin-free rhVTN.
- This accessible purification technique supports diverse cell culture needs, from research to clinical production.
- The optimized process enables widespread use of bioactive rhVTN in sensitive biological applications.
